About
Marker Therapeutics develops multi-antigen recognizing T cell therapies for blood cancers and solid tumors using their MAR-T cell technology, with clinical-stage programs including MT-601 targeting lymphoma patients.
Explore Marker Therapeutics Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.